Fintel reports that on September 17, 2025, Barclays initiated coverage of C4 Therapeutics (NasdaqGS:CCCC) with a Overweight recommendation.
Analyst Price Forecast Suggests 333.72% Upside
As of September 13, 2025, the average one-year price target for C4 Therapeutics is $14.79/share. The forecasts range from a low of $3.03 to a high of $52.50. The average price target represents an increase of 333.72% from its latest reported closing price of $3.41 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for C4 Therapeutics is 39MM, an increase of 13.19%. The projected annual non-GAAP EPS is -2.88.
What is the Fund Sentiment?
There are 211 funds or institutions reporting positions in C4 Therapeutics. This is an decrease of 36 owner(s) or 14.57% in the last quarter. Average portfolio weight of all funds dedicated to CCCC is 0.03%, an increase of 14.94%. Total shares owned by institutions decreased in the last three months by 18.25% to 56,982K shares. 
The put/call ratio of CCCC is 0.07, indicating a bullish outlook.
What are Other Shareholders Doing?
Wasatch Advisors holds 7,425K shares representing 10.43% ownership of the company. In its prior filing, the firm reported owning 6,724K shares , representing an increase of 9.43%. The firm decreased its portfolio allocation in CCCC by 7.40% over the last quarter.
Lynx1 Capital Management holds 7,098K shares representing 9.97% ownership of the company. No change in the last quarter.
Soleus Capital Management holds 6,979K shares representing 9.81% ownership of the company. No change in the last quarter.
Orbimed Advisors holds 6,830K shares representing 9.60% ownership of the company. No change in the last quarter.
WAMCX - Wasatch Ultra Growth Fund Investor Class shares holds 5,150K shares representing 7.24% ownership of the company. In its prior filing, the firm reported owning 4,556K shares , representing an increase of 11.53%. The firm increased its portfolio allocation in CCCC by 12.36% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
